News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
June 3, 2024 6:30 PM
EDT
2024
Aurinia Provides Update on Proxy Statement
Download
May 30, 2024 6:00 AM
EDT
2024
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Download
May 14, 2024 6:00 AM
EDT
2024
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Download
May 9, 2024 6:00 AM
EDT
2024
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Download
May 7, 2024 6:00 AM
EDT
2024
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Download
May 2, 2024 6:00 AM
EDT
2024
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Download
May 1, 2024 6:00 AM
EDT
2024
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Download
April 30, 2024 6:00 AM
EDT
2024
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Download
April 16, 2024 10:48 AM
EDT
2024
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Download
April 15, 2024 6:00 AM
EDT
2024
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
Download
February 29, 2024 8:30 AM
EST
2024
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
Download
February 27, 2024 8:30 AM
EST
2024
Aurinia to Participate in Upcoming Investor Healthcare Conferences (02/27/2024)
Download
February 15, 2024 6:00 AM
EST
2024
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
Download
February 5, 2024 8:30 AM
EST
2024
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
Download
January 5, 2024 6:00 AM
EST
2024
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
Download
December 19, 2023 4:30 PM
EST
2023
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
Download
November 6, 2023 9:00 PM
EST
2023
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
Download
November 2, 2023 6:00 PM
EDT
2023
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS® for Managing Lupus Nephritis
Download
November 2, 2023 6:00 AM
EDT
2023
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
Download
October 26, 2023 3:00 PM
EDT
2023
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
Download
October 19, 2023 6:00 AM
EDT
2023
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
Download
October 13, 2023 12:00 PM
EDT
2023
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
Download
October 12, 2023 5:30 PM
EST
2023
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
Download
September 21, 2023 6:00 AM
EDT
2023
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
Download
August 21, 2023 6:00 AM
EDT
2023
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.